Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 7/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.43 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | F10 | P00742 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4713168 | 0.89 | SRC (0.47) | SRCALDH1A1MAPK10PPP1CANPC1 | |
| SCHEMBL4711472 | 0.88 | SRC (0.45) | SRC | |
| SCHEMBL4711663 | 0.86 | CNR1 (0.50) | SRC | |
| SCHEMBL4715388 | 0.83 | CNR1 (0.49) | SRCALDH1A1MAPK10PPP1CAMEN1 | |
| SCHEMBL4714924 | 0.80 | CNR1 (0.52) | SRC | |
| SCHEMBL4715084 | 0.80 | CNR1 (0.52) | SRCPPP1CA | |
| SCHEMBL4713274 | 0.77 | CNR1 (0.44) | SRC | |
| SCHEMBL4715641 | 0.76 | SRC (0.48) | SRCPPP1CAATMMEN1KMT2A | |
| SCHEMBL4714461 | 0.74 | CNR1 (0.49) | — | |
| SCHEMBL4714991 | 0.74 | CNR1 (0.45) | SRCPPP1CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040214856-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC | 2004-10-28 | — | — | US | claimed |
| EP-1622903-B1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | PFIZER PROD INC (US) | 2008-10-01 | — | — | EP | disclosed |
| EP-1622903-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | Pfizer Products Inc. (US) | 2006-02-08 | — | — | EP | disclosed |
| WO-2004094421-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | PFIZER PRODUCTS INC. (US) | 2004-11-04 | — | — | WO | disclosed |
| US-20040214856-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC | 2004-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214856-A1 | Cannabinoid receptor ligands and uses thereof | CNR1, CNR2, GPR18 | SRC 1876/4885ALDH1A1 1920/4885MAPK10 1850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.